Phoenix, Sept. 20, 2016 (GLOBE NEWSWIRE) -- / BioNovelus, Inc. (PINKSHEETS: ONOV) is pleased to announce that we have retained Mr. John Fournier as our Environmental Protection Agency (EPA) specialist. Currently, Mr. Fournier is a consultant at Acadia Regulatory Consulting LLC. He will be responsible for seeking the EPA registration for CR-10 and its variations for other applications.
Mr. John Fournier’s position with the EPA was with the Biopesticides and Pollution Prevention Division (BPPD), in Arlington, VA. There, he managed the registration of biochemical pesticide products and new active ingredients.
John has worked for Marrone Bio Innovations, where he prepared, submitted, and shepherded registration dossiers through the EPA, including the Quagga & Zebra Mussels control product named Zequanox.
John worked closely with consultants, legislators, industry representatives, and lobbyists to achieve favorable and timely registrations and product placements. He represented Marrone Bio Innovations at meetings with state, national, and international regulatory agencies, including US EPA, FDA, PMRA, UK HSE, OECD, EMBRAPA Brazil, and state agencies.
John is a member of the Biopesticide Industry Alliance (BPIA); he works with BPIA member companies and EPA/PMRA to improve registration timelines.
Update on CR-10 Pilot Testing in Mexico and Costa Rica
Our Mexican strategic partner’s research and development team, specializing in bio pesticides, has been testing CR-10 on various fungi, bacteria and spores affecting coffee and other crops. Some of these pathogens are affecting North American crops as well.
Coffee rust has returned with the rainy season to Costa Rica; especially in the Perez Zeledon region. Management believes that climate change and coffee rust will have a significant impact on this year’s coffee production. Crop harvesting began this month and will finish sometime in February 2017.
In the Perez Zeledon region, three out of the six coffee plantations testing CR-10 since mid-February 2016 show no significant signs of reinfection (less than 5%). Of course, less rainfall may have also contributed to the eradication of the rust-free plantations. The coffee plants in the other three farms experienced a reduction in coffee-rust infection from previous years.
About BioNovelus Inc.
BioNovelus, Inc. (PINKSHEETS: ONOV) is a bioscience company that honors the environment with an innovative, cost effective and disruptive technology-based solution to agricultural and water problems.
BioNovelus’ primary target market is the $100Billion* plus, annually, worldwide, coffee industry. (*Source: Business Insider) Coffee Rust or "Roya" (Hemileia vastatrix), is a devastating fungus attacking the Arabica plant, currently, the coffee industry’s greatest threat. Billions of dollars and hundreds of thousands of industry jobs have been lost throughout Central America since 2012. (Source: ICafé)
This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2016 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events.
There is no assurance of if and when EPA approval will be obtained for CR-10 and various applications. There is no assurance that the positive testing on the six coffee plantations will be duplicated on other plantations and the impact less rain fall has versus the CR-10 product.
Factors that could cause the Company’s results to differ materially from forward looking statements regarding EPA approval and the efficacy of the CR-10 results a delay in EPA approval include the lack of capital needed to complete testing, the lack of experience with pursuing approval of this product and modifications that may be demanded by the EPA of the CR-10 formula. Factors that could cause lower rates of success in CR-10 eradication of fungi in other plantations include the method and timing of applications of CR-10, the impact of heavy rain fall the strength of fungi contamination, and other environmental conditions resulting in re-infection.
Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company's products and services, general business and economic conditions beyond the Company's control the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information, since these statements may no longer be accurate or timely.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
For additional information: http://bionovelus.com
Last updated on: 21/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.